Biosimilar competition is key to patient access and treatment cost of biologics
The European pharmaceutical industry welcomes the first yearly update on "Impact of Biosimilar competition" launched by IMS Health on October 6. It was prepared in close cooperation with the European Commission and with initial contributions from EFPIA, EBG, and EuropaBio. Based on 2014 data, it describes the effects of biosimilar competition on price and volume in Europe and offers an independent, neutral source of information on which evidence-based policy discussions should be launched. Discover five key takeaways and the European pharmaceutical industry's expectations.
Organic farms alone cannot feed the world
Will it be possible to increase global agricultural production to feed nearly three billion more people (approximately the total population in 1930)? Yes, but only if we put an end to ideological turf battles. The idealised notion that organic farms alone can feed the world is a long way from reality. On the other hand, there are limits to transferring modern agricultural production methods to every country. It is important to understand that these are not “alternatives”: the world does not have to choose between small-scale organic farming and advanced farming using high-tech innovations. Read more on TradeTalk
|
